Home » BIOVAIL'S TRAMADOL ER RECEIVES FDA APPROVAL
BIOVAIL'S TRAMADOL ER RECEIVES FDA APPROVAL
The FDA has approved Biovail's new drug application for a once-daily formulation of Tramadol ER (tramadol HCl). The product has been approved for the treatment of moderate to moderately severe chronic pain in once-daily 100-, 200- and 300-mg dosage strengths. Biovail said it is actively involved in negotiations related to the commercialization of Tramadol ER by a strategic marketing partner. The company expects to conclude these negotiations soon, and anticipates the commercial launch of Tramadol ER to occur in early 2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May